The Global Fever

Tech

Isomorphic Labs Raises $5 Billion in Biotech's Largest Venture Round

Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia. Reports call it the largest venture round in biotech history, six months after a $2.1 billion Series B.

Wasif Mumtaz

Founder and Editor · November 23, 2026 · 5 min read

Gloved hand using a pipette over laboratory glassware, representing drug discovery research
Photo: Magnific

Isomorphic Labs funding reached a new high on November 17, when the London-based drug design company announced a $5 billion Series C round. Outlets including R&D World and Fierce Biotech describe it as the largest venture round in biotech history. The company spun out of Google DeepMind, is backed by Alphabet, and says the money will expand its AI drug-design engine and move its own therapeutic programs toward human trials.

The round came about six months after a $2.1 billion Series B in May 2026, so Isomorphic has raised more than $7 billion across two rounds this year. The size is unusual even by the standards of the AI boom. It raises a simple question: what does a company that, according to reports, has not yet put a drug into human trials need $5 billion for?

Who invested and what they bought

The Series C was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, and Thrive Capital, GV and CapitalG took part, according to reports on the round. GV and CapitalG are Alphabet's venture and growth investment arms, which fits the company's Alphabet backing.

Isomorphic did not disclose a valuation. Bloomberg reported earlier in November that the company was raising at a valuation of about $50 billion, but the company has not confirmed that figure. Treat it as a report and not as a number the company has stated.

A Series C is a later-stage funding round. Investors at this stage are normally buying into a company that has shown technical progress and is preparing for a more expensive phase of work. For a drug developer, that phase is clinical testing, the point where a candidate medicine is tried in people.

How the round compares with earlier records

Reports compare the $5 billion figure with the $3 billion that Altos Labs raised at its 2022 launch, which had been the biotech record. A BIA executive quoted in coverage called the Isomorphic round the largest venture capital raise ever in life sciences. By that measure, the Series C passes the old mark by $2 billion.

The Series B in May was itself large. BioSpace described the $2.1 billion round at the time as the second largest biotech round ever. One report gives a different figure for the Series B, $1.2 billion, but most coverage, including Fierce Biotech's headline on the new round, uses $2.1 billion, and that is the number used here.

Records in venture funding depend on how a round is counted. The sources reviewed do not say whether the full $5 billion has been received or will arrive in stages, so the record rests on the announced total.

How the funding unfolded

The sequence was fast. Isomorphic announced its $2.1 billion Series B in May 2026. Bloomberg reported earlier in November that the company was raising at about $50 billion. The $5 billion Series C followed on November 17. City AM called it one of the biggest funding rounds in UK technology, which reflects that the company is based in London, and Sifted, which covers European startups, reported that Sequoia and Andreessen Horowitz backed it.

What Isomorphic Labs does

Isomorphic Labs designs drugs using artificial intelligence. The company says the new money will go toward expanding its AI drug-design engine and moving its therapeutic programs toward human trials. Companies of this kind earn money by developing medicines and then selling or licensing them, so their value depends on whether those medicines work.

Reports on the round note that it is one of the largest private checks ever written to a company that has yet to put a drug into human trials. That is the main risk the investors are accepting. Laboratory results and computer predictions do not guarantee that a drug will be safe or effective in people, and most candidate medicines never reach patients.

Why drug discovery needs so much capital

Developing a medicine involves years of laboratory research, safety testing and multi-phase clinical trials, and each stage costs more than the one before it. A company that wants to run several programs at once needs money for scientists, computing power, laboratory work and trials at the same time. The sources do not break down how Isomorphic will split the $5 billion among these uses.

Raising this much this fast also raises the bar. The company has said the money will move its programs toward human trials, and investors will watch for dates and data instead of further news about funding. The sources reviewed here do not give a trial start date.

Where this sits in the AI funding picture

Large private rounds like this one now sit alongside record public offerings. Anthropic priced its $81.3 billion IPO the day after Isomorphic's announcement, as covered in our report on Anthropic's Nasdaq debut. The two events show money moving into AI at both ends of the market, from private funding for drug discovery to the largest stock market listing on record.

What to watch next

Three things will show whether the money is well spent. First, whether Isomorphic gives a date for its first human trial and names the diseases it is targeting. Second, whether it confirms a valuation, which would show how the market prices a drug developer with no approved medicine. Third, whether further large rounds follow, either for Isomorphic or for competitors in AI drug design.

For readers outside biotech, the practical takeaway is narrower than the headline. The round is a statement of investor confidence, not a result. The company's value will depend on medicines that work, and according to the reporting reviewed here none has reached human trials yet.

Readers should also keep the round in proportion. A $5 billion raise is large in absolute terms, but it is a commitment of capital to research and trials, and the reports reviewed here do not describe any income from medicines. Progress will be measured in laboratory and clinical milestones, not in funding headlines.

Frequently asked questions

How much did Isomorphic Labs raise?

Isomorphic Labs raised $5 billion in a Series C round announced on November 17, 2026. It followed a $2.1 billion Series B about six months earlier.

Who led the Isomorphic Labs round?

Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz joined as a new investor, and Thrive Capital, GV and CapitalG took part.

What is Isomorphic Labs worth?

The company did not disclose a valuation. Bloomberg reported earlier in November that it was raising at about $50 billion, but that figure is unconfirmed.

Is this really the largest biotech venture round ever?

Several outlets say so. Reports compare it with the $3 billion Altos Labs raised at its 2022 launch, which had been the record.

What will Isomorphic do with the money?

The company says it will expand its AI drug-design engine and move its therapeutic programs toward human trials. It has not published a detailed spending plan.

ShareXLinkedInWhatsApp

Sources

Related stories

Tech

Anthropic IPO Process: Reuters Details Project Lantern Banker Complaints

Reuters reports that Anthropic's IPO, code-named Project Lantern, came with a compressed timeline, rushed approvals and unusual limits on bankers. Anthropic declined to comment.

Tech

AI Server Prices: Dell, HPE, Lenovo and Supermicro Reportedly Seek Up to 45% More

Dell, HPE, Lenovo and Supermicro are reportedly asking AI server buyers for up to 45% more months after signing, citing memory costs, the Financial Times says.

Tech

AI Funding Keeps Flowing as Isomorphic, DeepSeek and ByteDance Line Up Billions

Isomorphic Labs raised $5 billion, DeepSeek is reported to have raised about $15 billion and ByteDance plans a $6 billion buyback, even as AI stocks fell.